TIL therapy Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines tumor-infiltrating lymphocyte therapy, in which immune cells taken from a tumor are expanded outside the body and returned to the patient, now approved for melanoma and moving toward lung cancer and other solid tumors. It tests how fast commercial uptake and new indications turn into scaled revenue, and which participants capture value among developers, large pharmaceutical companies, treatment centres and manufacturing suppliers.

Commercial uptake in melanoma is now visible in reported revenue. Iovance Biotherapeutics reported FY2025 total revenue of about USD 264 million, of which US Amtagvi revenue was about USD 220 million and Proleukin revenue about USD 44 million, with Q4 2025 product revenue of about USD 87 million, roughly 30% above Q3. The company posted a net loss of USD 391.0 million in the same year. The conclusion is that a single TIL product has moved past the launch year with growing sales, and the cost of building the supply chain still exceeds the revenue it brings.

Growth continued in 2026. First quarter total revenue was USD 71 million, up about 45% from a year earlier, with Amtagvi revenue of USD 60 million, up 38%. Management guided to USD 79 million to USD 81 million of Amtagvi revenue in the second quarter and USD 350 million to USD 370 million of combined Amtagvi and Proleukin revenue for 2026, and targeted 110 authorised treatment centres by the end of 2026 with a shift toward community hospitals. The conclusion is that the number of treatment centres, not product supply, now sets the pace of uptake, and spreading beyond academic centres is the next step.

Expansion beyond melanoma decides the size of the market. Lifileucel in previously treated non-squamous non-small cell lung cancer holds FDA Fast Track designation, with an interim objective response rate of 26% and a median duration of response not reached at more than 25 months of follow-up, and the company is targeting a US launch in the second half of 2027. Early phase II data show a 40% confirmed response rate in the first five patients with metastatic serous endometrial cancer, and a 50% confirmed response rate in early soft tissue sarcoma data. The conclusion is that lung cancer is the large indication that moves TIL therapy from a niche product to a mainstream solid tumor treatment, and the other tumors remain too early to count on.

The brief treats TIL therapy as an accelerating signal with a ten year horizon to 2036. It identifies which tumors, regions and operators scale first and what each means for developers, large pharmaceutical companies, treatment centres and suppliers. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Tumor-infiltrating lymphocyte therapy takes immune cells from a patient tumor, expands them to large numbers in a manufacturing facility and returns them to the patient after lymphodepletion, with interleukin-2 support.

The cells recognise many tumor targets without engineering, which suits solid tumors that vary between patients.

Turnaround from shipment of tissue to return of product is a key performance measure.

Uses are advanced melanoma, with non-small cell lung cancer, endometrial cancer and sarcoma under study.

The limits are toxicity of the regimen, treatment complexity, manufacturing time and cost. The period turns on whether lung cancer data support approval and whether community hospitals can deliver the treatment.

The TIL therapy market, covering approved tumor-infiltrating lymphocyte products and related treatment, cytokine support and development revenue in melanoma and other solid tumors, is valued at USD 0.3–0.5 billion in 2026 and is projected to reach USD 2.58–4.30 billion by 2036, at a CAGR of 24%.

The 2026 base rests on sales of the approved melanoma product, related cytokine sales and development revenue. Growth then follows a lung cancer launch, approvals outside North America and new solid tumor indications.

The forecast is sensitive to lung cancer trial results, treatment centre growth and manufacturing capacity. Regionally, North America leads on sales and trials, Europe on pending marketing authorisation, and Asia-Pacific on Australian review and Chinese developers.

The base case assumes lung cancer data support US accelerated approval for a launch in 2027 or 2028, with wider use from 2031. An accelerated case assumes early lung cancer approval and strong endometrial and sarcoma data, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes slower treatment centre growth and weaker lung data, holding growth at the bottom of the range.

Growth drivers

• Commercial uptake in advanced melanoma.
• Expansion into non-small cell lung cancer.
• Early data in endometrial and sarcoma tumors.
• Approvals outside the United States.

Enablers

• Authorised treatment centre network.
• In-house manufacturing capacity.
• Fast Track and accelerated approval routes.
• Academic trial networks.

Restraints and barriers

• Cost and complexity of treatment.
• Toxicity of the treatment regimen.
• Competition from other cell therapies and bispecific antibodies.
• Heavy losses at commercial stage developers.

The direction of TIL therapy is set by the need after checkpoint inhibitor failure, approvals and reimbursement, manufacturing internalisation and turnaround, treatment centre network growth, and expansion into lung and other solid tumors.

The key participants in TIL therapy include Iovance Biotherapeutics, Inc., Instil Bio, Inc., Obsidian Therapeutics, Inc., Lyell Immunopharma, Inc., Adaptimmune Therapeutics plc, Immatics N.V., Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences, Inc., AstraZeneca PLC, Pfizer Inc., Lonza Group Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Charles River Laboratories International, Inc., Terumo Corporation, Miltenyi Biotec B.V. & Co. KG, Grit Biotechnology Co., Ltd., National Cancer Institute, Netherlands Cancer Institute, University of Texas MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Health Canada, Therapeutic Goods Administration, Swissmedic, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, European Society for Medical Oncology, American Society of Gene and Cell Therapy, Alliance for Regenerative Medicine, Biotechnology Innovation Organization and Pharmaceutical Research and Manufacturers of America.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as TIL therapy matures.

Iovance leads on the only approved product, Instil Bio and Obsidian lead among engineered TIL developers, and Lonza, Thermo Fisher Scientific and Miltenyi Biotec lead among suppliers of cell processing. Competitive intensity is low in 2026 and rises with engineered TIL data and competing cell therapies.

Where value migrates.

In 2026 value sits with the owner of the approved melanoma product, because it holds the only commercial revenue and the treatment centre network. By 2031 it moves toward owners of lung cancer approvals, because the indication multiplies the eligible patient population. By 2036 it settles in multi-tumor TIL franchises with fast, low cost manufacturing. Margins hold for developers with in-house manufacturing and narrow for those that depend on contract capacity and long shipment cycles.

The signals converge on commercial uptake ahead of new indications. FY2025 revenue of about USD 264 million, 2026 guidance of USD 350–370 million and a Fast Track lung cancer programme support growth, while cost and complexity, toxicity and competing cell therapies limit the pace.

Structural limits show where progress could slow: cost and complexity of treatment, toxicity of the regimen, competition from other cell therapies and bispecific antibodies, and heavy losses at commercial stage developers. The brief therefore tracks four indicators: quarterly revenue, treatment centre count, lung cancer trial results, and approvals outside the United States.

Advanced melanoma first, then lung cancer, then endometrial cancer and sarcoma are the expected order of adoption.